Abstract:Introduction Large granular lymphocytic leukemia (LGLL) is a rare chronic lymphoproliferative disorder characterized by persistent clonal expansions of lymphocytes over an extended period in which nearly 80% of cases are T-cell large granular lymphocytic leukemia (T-LGLL) (Alaggio et al. 2022). The clinical and biological features of T-LGLL exhibit significant heterogeneity as it can manifest as either CD8+ or CD4+. Furthermore, T-LGLL is associated with the rearrangement of the T cell receptor (TCR), which can be categorized into αβ T-LGLL and γδ T-LGLL variants. Additionally, few studies have compared αβ T-LGLL and γδ T-LGLL displaying that γδ T-LGLL revealed a similar or more aggressive clinical manifestation than αβ T-LGLL (Bourgault-Rouxel et al. 2008; Sandberg et al. 2006; Barilà et al. 2020; Barila et al. 2023). Thus, in this study, we described the clinical and biological features of 56 γδ T-LGLL patients, comparing to 306 αβ T-LGLL patients from a single institute. Methods A total of 362 patients with a diagnosis of T-LGLL between July 2005 and July 2022 from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science. All the patients met the recommended diagnostic criteria for LGLL(Lamy, Moignet, and Loughran 2017). We conducted a retrospective analysis of patients' clinical data, laboratory examinations, treatment, and follow-up. Non-normal distribution data were expressed as a median and range. Comparisons of continuous variables in different subgroups were analyzed with the Mann-Whitney U test. A χ2 or Fisher exact test was used to compare categorical variables. OS and PFS was calculated using the Kaplan-Meier method and compared by the log-rank test. P value < 0.05 was considered significant. Follow-up was to death or all statistical analyses were performed using the statistical software SPSS 27. Results Out of the 362 consecutive patients identified with T-LGLL, 56 (7.5%) were γδ T-LGLL, while 306 (92.5%) were αβ T-LGLL. Overall, clinical findings were very similar between the two groups in terms of median age (55 vs 54, P = 0.536), sex ratio (1.2 vs 1.3, P = 0.543), severity of neutropenia [absolute neutrophil count (ANC) ≤ 1.5×109 /L: 53.5% vs 53.3%, P = 0.959], anemia [hemoglobin (HB) ≤ 120 g/L: 85.7% vs 79.4%, P = 0.275], thrombocytopenia [Platelet (PLT) ≤ 100×109 /L: 14.3% vs 15.4%, P = 0.837], splenomegaly (32.7% vs 37.6%, P = 0.497), and pure red blood cell aplastic anemia (32.1% vs 39.9%, P = 0.275). Additionally, no significant differences were found between γδ and αβ T-LGLL cases in the frequency of STAT3 mutation (54.2% vs. 39.1%, P = 0.168). However, CD4-/CD8- immunophenotype was more frequent in the γδ T-LGLL cohort compared to αβ T-LGLL (25% vs. 17.6%; P < 0.001). Among the 362 patients, 309 patients (85.3%) required treatment. About 50% of patients received cyclosporine (CsA) and nearly 30% of patients had methotrexate (MTX) in both groups. Our analysis revealed that the overall response rate (ORR) of CsA was higher in the γδ T-LGLL subtype compared to the αβ T-LGLL (ORR: 78.6% vs. 58.7%, P = 0.048), when no significant difference in ORR of MTX was found (ORR: 78.5% vs. 85.2%, P = 0.684). After a median follow-up of 48.8 months for γδ T-LGLL and 53.1 months for αβ T-LGLL, the median overall survival (OS) was not reached in either subtype. There was no difference in median OS between γδ T-LGLL and αβ T-LGLL (152.5 vs. 158.4 months, P = 0.525). Hb ≤ 90g/L, PLT ≤ 150×10^9/L, and the co-existence of other malignancies were associated with decreased OS by univariate analysis in 362 T-LGLL patients. Conclusion In conclusion, patients with γδ T-LGLL exhibited comparable clinical and biological characteristics to those with αβ T-LGLL subtypes. Both subtypes had similar response to CsA or MTX-based therapy. No statistically significant differences in OS were observed between the two subtypes. It is advisable to employ identical therapeutic strategies for the treatment of both γδ T-LGLL and αβ T-LGLL in future clinical practice.

Gamma-delta T-cell large granular lymphocytic leukemia in the setting of rheumatologic diseases

Simultaneous Presentation of Leukemic Non-Nodal Mantle Cell Lymphoma and Gamma-Delta T-Large Granular Lymphocytic Leukemia in a Patient with Rheumatoid Arthritis

Aleukemic variant of T-cell large granular lymphocyte leukemia in patients with rheumatoid arthritis - diagnostically challenging subtype

T-cell large granular lymphocytic leukaemia in rheumatoid arthritis

IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.

The emerging role of Rituximab in the treatment of large granular lymphocytic leukemia associated with rheumatoid arthritis: a single center experience

A modern view of LGL leukemia

Diffused Pulmonary Infiltrates with T-Cell Large Granular Lymphocytic Leukemia

Two Distinct Types Of Clinical Characteristics And Therapies For T-Cell Large Granular Lymphocyte Leukemia: A Report Of Seven Cases

Γδ and Αβ T-cell Large Granular Lymphocytic Leukaemia Have Similar Characteristics and Outcomes.

Aggressive T-cell large granular lymphocyte leukemia: a case report and review of the literature.

P1242: A TRUELY LEUKEMIC SUBPOPULATION IDENTIFIED BY SINGLE CELL SEQUENCING IN T LARGE GRANULAR LYMPHOCYTIC LEUKEMIA

The constitutive activation of STAT3 gene and its mutations are at the crossroad between LGL leukemia and autoimmune disorders

Isolated anemia in patients with large granular lymphocytic leukemia (LGLL)

[The clinical and laboratory features of 9 cases with gammadeltaT cell lymphoma or leukemia].

Gamma-delta T-cell acute lymphoblastic lymphoma/leukemia: a report of a rare entity

Detection of Clonal Lymphoid Receptor Gene Rearrangements in Langerhans Cell Histiocytosis

Lymphoma complicating rheumatoid arthritis: results from a French case–control study

Large Granular Lymphocytic Leukemia : Common Therapies and their Outcomes

Large Granular Lymphocytic Leukemia: Clinical Features, Molecular Pathogenesis, Diagnosis and Treatment

CD103+ γδ T cell large granular lymphocytosis in a patient with refractory celiac disease: a diagnostic enigma